News

How HIV spreads from DCs
Enlarge image

ResearchSpainSwitzerlandGermany

How HIV spreads from DCs

20.12.2012 - Spanish researchers have unraveled how HIV disperses throughout the body – and can block the process before it occurs.

In a previous publication with Swiss and German virologists, researchers headed by Nuria Izquierdo-Useros from the AIDS Research Institute IrsiCaixa in Barcelona discovered that the HI virus uses specific membrane lipids called gangliosides on their surface to enter dendritic cells (DCs) by modifying membrane fluidity. Based on these findings, they tried to make the DC’s membrane more rigid by using a dihydroceramide desaturase (Des-1) blocker, which they have filed for patent. The new approach seems promising because HIV has first to enter DCs to be passed to their target cells, the CD4 T lymphocytes, in a process termed trans-infection. Now, the Spanish team has identified the molecule on the surface of DCs that recognises and binds the gangliosides and allows HIV to be taken up by dendritic cells and transmitted to CD4 cells. The new study is published in the open access journal PLOS Biology.

In order to identify the precise molecule located on the membrane of the dendritic cells capable of capturing HIV, the researchers studied one family of proteins that are present on the surface of these cells, called Siglecs. It is known that these proteins bind to the gangliosides on the HIV surface. In the laboratory, they mixed the virus with dendritic cells that displayed different quantities of Siglec-1, and found that a higher quantity of Siglec-1 led to those dendritic cells capturing more HIV, which in turn allowed for enhanced transmission of HIV to CD4 T lymphocytes, a process called trans-infection.

The team then tried inhibiting the Siglec-1 protein. They found that the dendritic cells lost their capacity to capture HIV and, importantly, they also lost their ability to transfer HIV to CD4 T lymphocytes. With all these data, the scientists concluded that Siglec-1 is the molecule responsible for HIV entrance into the dendritic cells, and could therefore become a new therapeutic target. "We had the key and now we have found a lock," explains Javier Martínez-Picado. "Now we are already working on the development of a drug that could block this process to improve the efficacy of the current existing treatments against AIDS".

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/how-hiv-spreads-from-dcs.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK8.85%
  • HYBRIGENICS (F)0.94 EUR8.05%
  • IXICO (UK)31.50 GBP5.00%

FLOP

  • ARGEN-X (B)13.70 EUR-3.52%
  • VECTURA (UK)132.10 GBP-3.17%
  • SAREUM HOLDINGS (UK)0.72 GBP-2.70%

TOP

  • NORDIC NANOVECTOR (N)33.60 NOK37.1%
  • KARO BIO (S)43.00 SEK30.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK28.1%

FLOP

  • BIONOR PHARMA (N)0.42 NOK-26.3%
  • E-THERAPEUTICS (UK)11.50 GBP-14.1%
  • GW PHARMACEUTICALS (UK)519.00 GBP-12.8%

TOP

  • NICOX (F)10.31 EUR431.4%
  • SAREUM HOLDINGS (UK)0.72 GBP227.3%
  • GENMAB (DK)1095.00 DKK83.3%

FLOP

  • BB BIOTECH (D)44.55 EUR-82.8%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)96.20 GBP-71.9%

No liability assumed, Date: 30.08.2016